JP7285027B2 - 化合物、その薬学的に許容される塩又は立体異性体、その使用、及び薬物組成物 - Google Patents
化合物、その薬学的に許容される塩又は立体異性体、その使用、及び薬物組成物 Download PDFInfo
- Publication number
- JP7285027B2 JP7285027B2 JP2021552493A JP2021552493A JP7285027B2 JP 7285027 B2 JP7285027 B2 JP 7285027B2 JP 2021552493 A JP2021552493 A JP 2021552493A JP 2021552493 A JP2021552493 A JP 2021552493A JP 7285027 B2 JP7285027 B2 JP 7285027B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- reaction
- added
- amido
- oxalyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Description
Xは、N又はCR3から選択される。
mは、0、1又は2から選択される。
本発明の化合物の合成は、次の合成シナリオ(シナリオ1-4)を利用することができる。説明する方法は、実施例をより容易に理解するための例示的なシナリオ説明であり、本発明の範囲を制限するものではない。
実施例66:1、3、5-トリメチル-2-アミド-N-(ナフタレン-2-基)-4-(2-プロパルギルアミノ-オキサリル)-ピロール(化合物66)
生体内及び生体外の生物学的実験及び試験によると、本発明の化合物、特に好ましい化合物は、HBVウイルスに対して強い活性を有するとともに、一般に低い毒性を有し、生体内で良好な薬物動態特性を有し、薬としての明らかな優位特性を有する。本特許のすべての構造分子の構造活性分析によると、一般式分子は高活性、低毒性及び創薬可能性の高い一類分子構造を有するという結論が明確に得られる。
一、抗B型肝炎ウイルス活性及びHepG2.2.15細胞活性の実験
本実験では、リアルタイム蛍光定量PCR(qPCR)法によりHepG2.2.15細胞の上清中のHBV DNAの含有量を検出し、HepG2.2.15細胞での化合物の抗B型肝炎ウイルス活性を測定し、Cell-titer BlueによりHepG2.2.15細胞活性に対する試験化合物の影響を検出した。実験では、エンテカビル(entecavir、ETV)を参照化合物として実験の品質を監視した。
1日目に細胞を96ウェルプレートに播種し、2日目に化合物を加えて細胞を処理し、5日目に新しい化合物含有培養液に置き換え、8日目に上清を収集してDNAを抽出した。定量PCRでHBV DNAの含有量を検出した。
%inh.=(1-HBV copy number of sample/HBV copy number of 0.5% DMSO control)×100
EC50は、Graphpad Prismソフトウェアで分析した(four parameter logistic equations)。
化合物の濃度、プレート配置、化合物の処理プロセスは、抗ウイルス実験と一致した。細胞を化合物で処理してから6日後、細胞活性をCell-titer Blueで測定した。
%細胞活性=(サンプル蛍光読み取り値-培養液コントロールの蛍光読み取り値)/( DMSOコントロールの蛍光読み取り値-培養液コントロールの蛍光読み取り値)×100。
本発明の抗B型肝炎ウイルス(HBV)抑制剤は、ウイルスの転写を抑制して、抗ウイルスの効果を実現することができる。リアルタイム蛍光定量PCR(qPCR)法により、HepG2.2.15細胞の上清中のHBV DNAの含有量を検出し、HepG2.2.15細胞での化合物の抗B型肝炎ウイルス活性(EC50で表す。)を測定し、Cell-titer BlueによりHepG2.2.15細胞活性に対する試験化合物の影響(CC50で表す。)を検出した。次のレベルを使用した:抗B型肝炎ウイルス活性のEC50の場合、I: >50μM、II: ≦50μMかつ>5μM、III: ≦5μMかつ>0.5μM、IV: ≦0.5μMかつ>0.05μM、V: ≦0.05μM。通常のHepG2.2.15細胞活性のCC50の場合、実際の試験数値又は桁を表す数値を使用した。例えば、「>100μM」は、当該分子が細胞活性のCC50値に対して試験の最高濃度より大きいことを意味し、この試験で実際に使用された最高濃度は100μMであった。結果は表1に示した。文献では、Cpd 7a(WO 2017/156255 A1におけるCompound 7a)は高活性の抗B型肝炎ウイルス(HBV)抑制剤であり、正常細胞の活性に対して明らかな影響がないと報告している。Cpd 7aを対照として、本発明の化合物とともに試験した。本発明の化合物は、ウイルスの転写を効果的に抑制し、正常なHepG2.2.15細胞活性に明らかな影響を与えることなく抗ウイルスの効果を実現することができる。
1、実験方法
体重215~343グラムの雄性SDラットを使用し、試験前に一晩絶食させた。試験化合物を総量5%のDMSOに完全に溶解し、さらに30%のCaptisolで2mg/mLに希釈し、20mg/kgで胃内投与した。投与後15分、30分、1、2、4、6、8、24時間後に、各時点で尾端を切って約0.3mlの血液を採取し、K2-EDTAを含有する遠心分離管に入れ、遠心分離(3500rpm、10分、4°C)してから-80℃の超低温冷蔵庫に保存した。50μLの血液サンプルを135ミリリットルのアセトニトリル(内部標準ISを含む。)と混合し、30sボルテックスし、15000rpm 4°Cで10min遠心分離し、10ミリリットルの上清を採取してLC-MS/MSに注入して分析した。
本発明で提供する化合物2、化合物8、化合物11、化合物36、化合物42は、ラットへの経口投与後、十分に吸収され、血液曝露量が高かった。結果は図1及び表2に示した。本発明の化合物のTmaxは0.5~1.67時間、Cmaxは3673~9433ng/mlで、参照化合物Cpd 7a Cmaxの2.1~5.3 倍であり、AUC0-24hは17113-87187ng/ml*hで、参照化合物Cpd 7a AUC0-24hの1.4~7.2倍である。Cmaxは最大血中濃度、T1/2は半減期、AUC0-24は0~24時間の時間-濃度曲線下面積、AUC0-infは0-Inf時間-濃度曲線下面積である。
Claims (8)
- B型肝炎ウイルス(HBV)感染を治療、根絶、減少若しくは抑制し、又はHBV感染による肝損傷を軽減するための請求項1に記載の化合物、その薬学的に許容される塩又は立体異性体。
- 請求項1~2のいずれか1項に記載の化合物、その薬学的に許容される塩又は立体異性体、及び薬学的に許容される添加剤を含む薬物組成物。
- 前記添加剤は、賦形剤、希釈剤、崩壊剤、流動促進剤及び潤滑剤のうち少なくとも1つから選択され、前記添加剤には、リン酸二カルシウム、セルロース、圧縮性糖、リン酸水素カルシウム脱水物、乳糖マンニトール、微結晶セルロース、デンプン及び/又はリン酸三カルシウムが含まれることを特徴とする請求項3に記載の薬物組成物。
- 一種又は多種の抗ウイルス剤をさらに含み、
抗ウイルス剤は、B型肝炎ウイルス(HBV)ポリメラーゼ抑制剤、インターフェロン、ウイルス侵入抑制剤、ウイルス成熟抑制剤、アセンブリモジュレーター、逆転写酵素抑制剤、TLR-アゴニストから選択される少なくとも一つである
ことを特徴とする請求項3に記載の薬物組成物。 - 前記逆転写酵素抑制剤は、エンテカビル(Entecavir)、テノホビル(Tenofovir)、HepDirect-テノホビル、エントリシタビン(Entricitabine)、アデホビル(Adefovir)、HepDirect-アデホビル(Pradefovir)、アシクロビル(Acyclovir)、ガンシクロビル(Ganciclovir)、GS-7340(TAF)、ベシフォビル(Besifovir)、Birinapant(HY-16591)、リバビリン(Ribavirin)及びエファビレンツ(Efavirenz)から選択される少なくとも一つである
ことを特徴とする請求項5に記載の薬物組成物。 - HBV感染を治療、根絶、減少若しくは抑制し、又はHBV感染による肝損傷を軽減するための薬物の調製における請求項1~2のいずれか1項に記載の化合物、その薬学的に許容される塩若しくは立体異性体の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023079878A JP2023103364A (ja) | 2019-11-13 | 2023-05-15 | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911103300 | 2019-11-13 | ||
CN201911103300.1 | 2019-11-13 | ||
CN201911154337.7 | 2019-11-22 | ||
CN201911154337 | 2019-11-22 | ||
PCT/CN2020/073160 WO2021093172A1 (zh) | 2019-11-13 | 2020-01-20 | Hbv抑制剂及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023079878A Division JP2023103364A (ja) | 2019-11-13 | 2023-05-15 | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022522522A JP2022522522A (ja) | 2022-04-19 |
JP7285027B2 true JP7285027B2 (ja) | 2023-06-01 |
Family
ID=75911723
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021552493A Active JP7285027B2 (ja) | 2019-11-13 | 2020-01-20 | 化合物、その薬学的に許容される塩又は立体異性体、その使用、及び薬物組成物 |
JP2023079878A Pending JP2023103364A (ja) | 2019-11-13 | 2023-05-15 | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023079878A Pending JP2023103364A (ja) | 2019-11-13 | 2023-05-15 | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11903924B2 (ja) |
EP (2) | EP4245372A3 (ja) |
JP (2) | JP7285027B2 (ja) |
CN (2) | CN117903110A (ja) |
AU (1) | AU2020385034A1 (ja) |
WO (1) | WO2021093172A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116768776A (zh) * | 2022-03-17 | 2023-09-19 | 成都微芯药业有限公司 | 吡咯酰胺类化合物及其制备方法和用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016518437A (ja) | 2013-05-17 | 2016-06-23 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
JP2016525141A (ja) | 2013-07-25 | 2016-08-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | グリオキサミド置換ピロールアミド誘導体およびb型肝炎を処置するための医薬品としてのその使用 |
CN108250122A (zh) | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 |
CN109153640A (zh) | 2016-03-09 | 2019-01-04 | 埃默里大学 | 用抗病毒剂消除乙型肝炎病毒 |
CN109790168A (zh) | 2016-08-26 | 2019-05-21 | 吉利德科学公司 | 取代的吡咯嗪化合物及其用途 |
WO2019154343A1 (zh) | 2018-02-09 | 2019-08-15 | 正大天晴药业集团股份有限公司 | 衣壳蛋白装配抑制剂、其药物组合物和用途 |
WO2019185016A1 (zh) | 2018-03-30 | 2019-10-03 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019118358A1 (en) | 2017-12-11 | 2019-06-20 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
SG11202012346YA (en) * | 2018-06-11 | 2021-01-28 | Venatorx Pharmaceuticals Inc | Hepatitis b capsid assembly modulators |
-
2020
- 2020-01-20 JP JP2021552493A patent/JP7285027B2/ja active Active
- 2020-01-20 CN CN202311519900.2A patent/CN117903110A/zh active Pending
- 2020-01-20 CN CN202080091985.7A patent/CN114901639B/zh active Active
- 2020-01-20 AU AU2020385034A patent/AU2020385034A1/en active Pending
- 2020-01-20 EP EP23181595.2A patent/EP4245372A3/en active Pending
- 2020-01-20 WO PCT/CN2020/073160 patent/WO2021093172A1/zh active Application Filing
- 2020-01-20 US US17/593,632 patent/US11903924B2/en active Active
- 2020-01-20 EP EP20888204.3A patent/EP3919474B1/en active Active
-
2023
- 2023-05-15 JP JP2023079878A patent/JP2023103364A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016518437A (ja) | 2013-05-17 | 2016-06-23 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
JP2016525141A (ja) | 2013-07-25 | 2016-08-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | グリオキサミド置換ピロールアミド誘導体およびb型肝炎を処置するための医薬品としてのその使用 |
CN109153640A (zh) | 2016-03-09 | 2019-01-04 | 埃默里大学 | 用抗病毒剂消除乙型肝炎病毒 |
CN109790168A (zh) | 2016-08-26 | 2019-05-21 | 吉利德科学公司 | 取代的吡咯嗪化合物及其用途 |
CN108250122A (zh) | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 |
WO2019154343A1 (zh) | 2018-02-09 | 2019-08-15 | 正大天晴药业集团股份有限公司 | 衣壳蛋白装配抑制剂、其药物组合物和用途 |
WO2019185016A1 (zh) | 2018-03-30 | 2019-10-03 | 正大天晴药业集团股份有限公司 | 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2020385034A1 (en) | 2021-09-30 |
CN114901639A (zh) | 2022-08-12 |
EP4245372A3 (en) | 2023-11-22 |
EP3919474A1 (en) | 2021-12-08 |
WO2021093172A1 (zh) | 2021-05-20 |
EP4245372A2 (en) | 2023-09-20 |
US20220184035A1 (en) | 2022-06-16 |
US11903924B2 (en) | 2024-02-20 |
CN114901639B (zh) | 2023-11-24 |
JP2022522522A (ja) | 2022-04-19 |
EP3919474A4 (en) | 2022-06-01 |
CN117903110A (zh) | 2024-04-19 |
EP3919474B1 (en) | 2023-10-11 |
JP2023103364A (ja) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6861858B2 (ja) | Ssao阻害剤 | |
CN111484477B (zh) | 一种苯并吡啶酮杂环化合物及其用途 | |
CN107849037B (zh) | 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 | |
JP6506836B2 (ja) | B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン | |
JP7323603B2 (ja) | 三環式縮合フラン置換ピペリジンジオン系化合物 | |
JP7123429B2 (ja) | 二環式縮合環系ヌクレオカプシド阻害剤および薬物としてb型肝炎を治療するためのその使用 | |
CN108250122B (zh) | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 | |
CA2966250C (en) | Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof | |
JP2008525363A (ja) | プロスタグランジン媒介疾患治療のためのピリジン化合物 | |
CA2552002A1 (en) | Azabenzofuran substituted thioureas as inhibitors of viral replication | |
DK2599774T3 (en) | DEHYDRATED pyridine AS CB2 cannabinoid receptor ligands | |
JP2018508502A (ja) | 長時間作用型dpp−iv阻害剤とする置換のアミノ六員飽和ヘテロ脂環化合物 | |
JP2023103364A (ja) | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 | |
JP2021503466A (ja) | 抗HBVのテトラヒドロイソキサゾロ[4,3−c]ピリジン類化合物 | |
KR101941794B1 (ko) | 아미노설포닐계 화합물, 이의 제조 방법 및 용도 | |
RU2279433C2 (ru) | Новое соединение для лечения импотенции | |
JP2022531251A (ja) | ヒト免疫不全ウイルス複製阻害剤 | |
CN114075227B (zh) | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 | |
CN115175913B (zh) | 取代的双三环化合物及其药物组合物和用途 | |
CN116648240A (zh) | 一种环肽类病毒蛋白酶抑制剂,其制备方法,及其在抗病毒药物中的应用 | |
JP7198968B2 (ja) | チエノ[2,3-c]ピリダジン-4(1H)-オン系化合物の結晶形及びその製造方法並びに使用 | |
US20240139152A1 (en) | Hbv inhibitor and its use | |
JP7450951B2 (ja) | 新型fxr小分子作動剤の製造およびその使用 | |
TWI392677B (zh) | 抗病毒化合物、其製備方法及用途 | |
CN117088861A (zh) | 2-取代芳基-恶唑啉-4-酮衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210902 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230425 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230515 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7285027 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |